Item 4 — Purpose of Transaction
Item 3 of this Statement is incorporated herein by reference. The acquisitions by the Reporting Persons of the Issuer's securities as described herein were effected pursuant to the 2024 Subscription Agreement, the January 2025 Subscription Agreement and the October 2025 Subscription Agreement (collectively, the "Subscription Agreements"). The Reporting Persons acquired their securities for strategic investment purposes and in connection with (i) the purchase by Lantheus Holdings of all of the Issuer's rights to two licensed preclinical assets, a leucine-rich repeat-containing protein 15-targeted radiotherapeutic and a Trophoblast cell surface antigen-2-targeted radiodiagnostic on June 15, 2024 (the "June 2024 Purchase"), and (ii) strategic co-development partnerships with the Issuer to advance the clinical development of innovative radiopharmaceuticals in Australia (together with the June 2024 Purchase, the "Transfer and Development Transactions"). The June 2024 Purchase was effected pursuant to a Purchase and Development Agreement, dated May 23, 2024, between the Issuer, Radiopharm Theranostics (USA), Inc. and Lantheus Holdings (the "Purchase and Development Agreement"). Pursuant to the Purchase and Development Agreement, Lantheus Holdings paid an upfront payment of $2.0 million USD. In connection with this acquisition, Lantheus Holdings assumed the underlying license agreements related to the two preclinical assets, together with their respective milestone and royalty payment obligations. The Reporting Persons intend to continue to review their investment in the Issuer on an ongoing basis and, depending on various factors, including, without limitation, the Issuer's business, results of operations and financial position, the trading price of the Ordinary Shares, conditions in the capital markets and general economic, political and industry conditions, the Reporting Persons may, in the future, take such actions with respect to their Ordinary Shares as they deem appropriate, including, without limitation: purchasing additional Ordinary Shares; selling Ordinary Shares; or taking any other action with respect to the Issuer or any of its securities in any manner permitted by law or with respect to any and all matters referred to in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons are authorized to sell their Ordinary Shares subject to certain market conditions from time to time, in each case whether through privately negotiated transactions, open market transactions, block trades, registered offerings, underwritten transactions, accelerated transactions, derivative transactions, collars, prepaid forward transactions, swaps, exchange transactions, brokerage transactions or otherwise. Except as described in this Statement, neither of the Reporting Persons has any present plans or proposals that relate to or would result in any of the actions described above and in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position or their purpose or develop such plans.